General description
Rituximab is a monoclonal antibody used in treatment protocols for lymphomas and leukaemia, as well as various autoimmune inflammatory diseases.
INN
Rituximab
ATC codes
Medicine type
Biological agent
EML status history
First added in 2015
(TRS
994)
for
Diffuse large B-cell lymphomas
Added in 2015
(TRS
994)
for
Chronic lymphocytic leukaemia or small lymphocytic lymphoma
Added in 2015
(TRS
994)
for
Follicular lymphoma
Added in 2023
(TRS
1049)
for
Multiple sclerosis
Added in 2023
(TRS
1049)
for
Burkitt lymphoma including Burkitt leukaemia
Wikipedia
DrugBank
Recommendations
Section
Targeted therapies
- Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial
Section
Medicines for multiple sclerosis
- Parenteral > General injections > IV: 500 mg per 50 mL in 50 mL vial
Indications